Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03987919 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
A Phase 3 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,879
- Enrollment target
- 20
- Study locations
NCT03987919 is a Phase 3 study of Type 2 Diabetes that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,879 participants, above the 1,096-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (71% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT03987919, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,879 participants
- Enrollment target
- 20
- Study locations
Study Summary
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
Study Locations (20)
California
- National Research Institute - Huntington Park - Huntington Park
- Catalina Research Institute, LLC - Montclair
- Valley Clinical Trials, Inc. - Northridge
- National Research Institute - Huntington Park - Panorama City
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
- Artemis Institute for Clinical Research - San Marcos
- University Clinical Investigators, Inc. - Tustin
Florida
- Clinical Research of South Florida - Coral Gables
- East Coast Institute for Research at The Jones Center - Lake City
- South Florida Clinical Research Institute - Margate
- Suncoast Research Group - Miami
- New Horizon Research Center - Miami
- Oviedo Medical Research - Oviedo
- South Broward Research - Pembroke Pines
Alabama
- Cahaba Research - Birmingham
- Syed Research Consultants Llc - Sheffield
Georgia
- United Osteoporosis Center - Gainesville
- Sky Clinical Research Network - Union City
Connecticut
- CMR of Greater New Haven - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,879 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2021-02-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03987919
The ClinicalTrials.gov registry entry for NCT03987919 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,879 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,096-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (71% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT03987919 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT03987919 about?
NCT03987919 is a clinical study titled "A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes". The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
What is the current status of trial NCT03987919?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,879 participants. The study started on 2019-07-30. Estimated completion is 2021-02-15.
What conditions does trial NCT03987919 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT03987919?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT03987919?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03987919 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.